In this section of Hemophilia Village, you'll find information about ReFacto. ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes in patients with hemophilia A. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown.

The summary about ReFacto provides information to help you make informed recommendations to your patients with hemophilia A.

Read about the efficacy of ReFacto both for short-term routine prophylaxis, as in surgery, and for control of bleeding episodes.

Learn about the viral safety of ReFacto and how ReFacto is manufactured to protect patients from transmission of human blood-borne viruses.

Discover the convenience ReFacto can offer your patients.

Discover the difference that distinctive ReFacto packaging can make for your patients. And see how your patients and their families can benefit from special programs and services.

Your hemophilia A patients can try ReFacto free, through the ReFacto Trial Prescription Program.

Find answers to more of your questions about ReFacto in the FAQs section.

Indication
ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes in patients with hemophilia A. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown.

Important Safety Information

	•	As with the intravenous administration of any protein product, adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, tiredness, or symptoms of allergic reactions.
	•	The remote possibility exists for hypersensitivity to non-human mammalian proteins. Known hypersensitivity to mouse or hamster proteins may be a contraindication to the use of ReFacto.
	•	Allergic reactions such as hives, itching, difficulty breathing, rapid heart rate, light-headedness and anaphylaxis have been reported for all factor VIII products. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any of these symptoms occur.

Please see ReFacto Prescribing Information

The health information contained herein is provided for educational purposes only and is not meant to replace personal discussions between health care providers and patients. All decisions about patient care must be made with a health care provider who can assess the special needs of each individual patient.